Drugs / Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)
Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05574985 | Aug → Oct 2022 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05574985 ↗ |
| Modality | Vaccine | “Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)” NCT05574985 ↗ |